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ABSTRACT
OBJECTIVE: Coronavirus disease 2019 (COVID-19) pandemic is one of the deadliest pandemics of our time. Vaccines
are our best hope to put an end to this pandemic. An emergency use authorization (EUA) has been given to seven
vaccines and more than 4 billion doses have been globally administered. Because of EUA, the large-scale safety trials
were not conducted before their use and adverse effects were one of the chief concerns resulting in vaccine hesitancy.
METHODS: This is a retrospective observational study. All the inpatients admitted to the Department of Neurology, Aga
Khan University during the period from 1st April 2021 to 31st July 2021 with a recent history of COVID-19 vaccination
within previous 8 weeks were included in this study. Patients with the pre-existing neurological condition were
excluded.
RESULTS: Eleven patients were included in the study. Most of our patients were male (82%; n=9) with a median age
+ had
of 53 14.6 years. 6 of these patients received the Sinopharm vaccine and 2 received AstraZeneca. Six patients
–
stroke, two had cerebral venous thrombosis, and onepatient each had autonomic neuropathy, transverse myelitis, and
seizures. The majority of the patients presented within 4 weeks post-vaccination. No mortality was noted. The mean
discharge mRS was 1.1. Only one patient had a history of previous COVID-19 infection.
CONCLUSION: Almost three-quarters (73%) of inpatients with a recent COVID-19 vaccination had a cerebrovascular
disease. This may be a coincidental finding or may indicate a probable association. Our patients also had multiple risk
factors in addition to a recent history of COVID-19 vaccination. The potential neurological sequelae of the COVID-19
vaccine will be unraveled as the vaccinated population increases.
KEY WORDS: COVID-19; Vaccine; Stroke; CVT; Sinopharm; SinoVac
INTRODUCTION
Coronavirus disease 2019 (COVID-19) pandemic is
one of the deadliest pandemics of our time with
approximately 200 million confirmed cases and more
than 4 million global deaths, as of August 4, 2021.1 As
the cases continue to rise, vaccines are our best hope
to control this pandemic. Thus far, the World Health
Organization has given emergency use authorization
(EUA) to seven vaccines i.e. Pfizer/BioNTech, Moderna,
Oxford-AstraZeneca (AZ), Janssen (Johnson &
Johnson), Sinopharm, and Sinovac and more than 4
billion doses have been globally administered.1,2
COVID-19 vaccine drive in Pakistan initiated in February
2021 and more than 34 million and 7 million doses
have been administered in Pakistan and Sindh,
respectively.3,4 Because of EUA, the large-scale safety
trials were not conducted before their use and adverse
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effects were one of the chief concerns resulting in
vaccine hesitancy.
Reported neurological symptoms post-vaccination have
mostly been mild and occur shortly after vaccination.
Fatigue and headache were the most common
neurological symptoms reported one-week after a Pfizer
or AZ vaccination.5,6 Parallel studies on Sinovac and
Sinopharm vaccine recipients have also shown
headache to be the most common neurological
symptom (68%), followed by myalgias (60%).7 This was
largely an outpatient-based study.7 Recent reporting of
serious neurological complications such as cerebral
venous thrombosis (CVT), transverse myelitis, and
Guillain-Barre syndrome (GBS) have raised concerns
regarding the safety of these vaccines, with CVT being
a major concern, especially after AZ and Janssen
vaccination.8,9 Cases of Bells’ palsy, tremor, diplopia,
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former patient had hyperhomocysteinemia, however,
the cause of seizures in the latter patient remained
unknown despite extensive workup.
Two patients also presented after CanSino vaccine; one
with ischemic stroke and the second with transverse
myelitis. The remaining one patient who received
Sinovac also presented with an ischemic stroke. Both
patients with ischemic stroke had vascular risk factors.
Table 1 shows a summary of the patients.

tinnitus, seizures, and reactivation of herpes zoster
have been also reported in post-vaccinated
patients.10,11 The objective of our study is to look for
spectrum of neurological disorders in admitted patients
with a recent history of COVID-19 vaccination in our
population. Secondly, a majority of our population
received inactivated COVID-19 vaccine i.e. Sinopharm
and Sinovac, in the first phase of vaccination. The
published literature regarding the serious adverse
effects of inactivated COVID-19 vaccines is limited and
our study will provide a useful tool to highlight these
probable adverse effects.

DISCUSSION
Concerns regarding the safety of COVID-19 vaccines
were raised when multiple cases of thromboembolism
(n=11), especially CVT (n=9), were initially reported
among AZ vaccine recipients (82% females) in early
March 2021.8 This resulted in a temporary suspension
of AZ vaccination and an investigation was conducted.
By the end of March 2021, around 62 cases of CVT
cases post-AZ vaccine were reported by the EU safety
database.13 Most of these patients had serum
antibodies against platelet-factor 4 (PF4) and it was
suggested that an immune response to PF4 is
responsible
for
the
higher
incidence
of
thromboembolism in these patients.14 In another study,
two patients developed transverse myelitis post-AZ
vaccine.15 Besides AZ, cases of thromboembolism are
also seen in the Janssen vaccine recipients.
Interestingly, most of these cases of thromboembolism
and CVT occurred in young women with a median age
of 37 years and within two weeks post-vaccination.
Both AZ and Janssen have been reinstated for use as
the benefits greatly outweigh the risks.10 An unusual
case of new-onset refractory status epilepticus was
reported in a 42-year-old female 10 days after the first
dose of the AZ vaccine, who had no prior comorbid.16
The data regarding adverse effects following inactivated
COVID-19 vaccines (Sinopharm, SinoVac, and
CanSino) is limited. A cross sectional study from UAE
on subjects receiving Sinopharm vaccine (n=1000)
reported mild adverse effects of fatigue, injection site
reaction, and headache.17 Two other studies reported
mild side effects including myalgias, fever and
headache within 20 hours post-vaccination in 24% and
16% of subjects receiving Sinopharm, respectively.18,19
None of the side effects were serious or required
hospitalization. At present, there is no published data
to support serious adverse events following Sinopharm,
Sinovac or CanSino vaccine. However, all patients in
our study presented with serious symptoms following a
recent
COVID-19
vaccination
that
required
hospitalization. No mortality was reported and all
patients improved and were discharged home in a
stable condition.
Our study has certain limitations. Our study is a
single-center study, consisting only of admitted

METHODS
This is an observational cross-sectional study. All the
patients admitted to the Department of Neurology, Aga
Khan University, Pakistan during the period from 1st April
2021 to 31st July 2021 with a recent history of
COVID-19 vaccination during the past eight weeks were
included in this study. Patients with pre-existing
neurological conditions were excluded. This study was
approved by the Ethical Review Committee of the AKUH
and informed consent requirement was waived.
Statistical analysis was performed using IBM Statistical
Package for Social Sciences (SPSS) Statistics for
Windows, Version 26.0. (Armonk, NY: IBM Corp).
Results were presented as frequency and percentages
for qualitative variables and mean and standard
deviation for quantitative variables.
RESULTS
Eleven patients were included in our study. Most of our
patients were male (82%; n=9) with a median age of
53 14.6 years (range: 30 – 79 years). Six of these
patients received the Sinopharm vaccine, two patients
each received AZ and CanSino, while one patient
received Sinovac vaccine. Half of the patients had only
received the first dose, with CanSino vaccine being
administered on a single-dose regimen. The majority of
the patients (82%, n=9) presented within 4 weeks
post-vaccination (mean 3.5 weeks). No mortality was
noted. The mean discharge mRS was 1.1. Only one
patient had a history of COVID-19 infection.
Six patients presented after the Sinopharm vaccine; 3
had an ischemic stroke, 1 patient each had a left basal
ganglia hemorrhage, CVT, and autonomic neuropathy.
The latter was subsequently diagnosed with multiple
myeloma. The patients with ischemic stroke had
vascular risk factors (DM, HTN, IHD). Patient with CVT
also had hyperhomocysteinemia, which is associated
with an increased risk for CVT.12
Of the two patients presenting after AZ; one had CVT,
and the second patient presented with seizures. The
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patients. We had a small number of patients with a
cross-sectional observational study design. Most of the
patients also had multiple risk factors for their
neurological syndromes. Hence, a cause-and-effect
relationship cannot be established.
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CONCLUSION
Almost three-quarters (73%) of our inpatients with a
recent COVID-19 vaccination had a cerebrovascular
disease. This may be a coincidental finding or may
indicate a probable association. This should be further
investigated and looked for in other centers as
well.However, only time will unravel the potential
neurological sequelae of COVID-19 vaccines,
particularly as the vaccinated population increases.
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ABBREVIATIONS:
A/G = Age/Gender; AZ = Astrazeneca; COVID-19 = Coronavirus disease 2019; CVT = Cerebral venous thrombosis; DM =
Diabetes mellitus; F = Female; HTN = Hypertension; IHD = Ischemic heart disease; LAMA= Left against medical advice; M
= male; MCA = Middle cerebral artery; mRS= Modified Rankin Score; PH = Past history; PICA = Posterior inferior cerebellar
artery *Time between last vaccine dose and symptoms
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